ELOVL7 — Elongation of Very Long Chain Fatty Acids 7

ELOVL7 — Elongation of Very Long Chain Fatty Acids 7

Introduction

The ELOVL7 gene (Elongation of Very Long Chain Fatty Acids 7) encodes a member of the ELOVL family of enzymes responsible for the first and rate-limiting step of very-long-chain fatty acid (VLCFA) elongation. VLCFAs (≥22 carbons) are essential components of neuronal membranes, myelin sheaths, and play important roles in brain function and neurodegenerative diseases.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ELOVL7 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ELOVL7</td></tr>
<tr><td><strong>Full Name</strong></td><td>Elongation of Very Long Chain Fatty Acids 7</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>5p12</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[199870](https://www.ncbi.nlm.nih.gov/gene/199870)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000164181</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9H5Q3](https://www.uniprot.org/uniprot/Q9H5Q3)</td></tr>
<tr><td><strong>Protein Size</strong></td><td>299 amino acids</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Protein Structure and Function

ELOVL7 — Elongation of Very Long Chain Fatty Acids 7

Introduction

The ELOVL7 gene (Elongation of Very Long Chain Fatty Acids 7) encodes a member of the ELOVL family of enzymes responsible for the first and rate-limiting step of very-long-chain fatty acid (VLCFA) elongation. VLCFAs (≥22 carbons) are essential components of neuronal membranes, myelin sheaths, and play important roles in brain function and neurodegenerative diseases.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ELOVL7 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ELOVL7</td></tr>
<tr><td><strong>Full Name</strong></td><td>Elongation of Very Long Chain Fatty Acids 7</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>5p12</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[199870](https://www.ncbi.nlm.nih.gov/gene/199870)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000164181</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9H5Q3](https://www.uniprot.org/uniprot/Q9H5Q3)</td></tr>
<tr><td><strong>Protein Size</strong></td><td>299 amino acids</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Protein Structure and Function

The ELOVL7 gene is located on chromosome 5p12 and encodes a 299-amino acid membrane-bound enzyme in the endoplasmic reticulum. The protein contains multiple transmembrane domains and a conserved HXXHH motif essential for catalytic activity.

Expression Pattern

ELOVL7 shows highest expression in:

• Liver - Primary site of fatty acid metabolism
• Brain - [Neurons](/entities/neurons) and glia
• Kidney - Steroid hormone synthesis
• Heart - Cardiac metabolism
• Adipose tissue - Lipid storage

Molecular Function

Catalytic Activity

Substrate Specificity

• Preferred substrates - C16:0, C18:0, C18:1, C18:2, C20:4
• Products - C22-C26 fatty acids
• Specialization - Prefers saturated and monounsaturated fatty acids

Disease Associations

Alzheimer's Disease

• Membrane composition - Altered VLCFA metabolism in AD brains
• Amyloid processing - Lipid rafts affected by fatty acid composition
• Cognitive decline - Correlations with disease progression
• Therapeutic potential - Targeting VLCFA metabolism

Parkinson's Disease

• Mitochondrial function - Lipid metabolism affects mitochondrial membranes
• [Alpha-synuclein](/proteins/alpha-synuclein) - Lipid interactions with α-syn aggregates
• Neuroprotection - Potential therapeutic targeting

Other Neurological Disorders

• Multiple sclerosis - Myelin VLCFA content
• Epilepsy - Altered fatty acid metabolism
• Stroke - Ischemia affects lipid metabolism

Metabolic Disorders

• Insulin resistance - ELOVL7 in metabolic syndrome
• Dyslipidemia - Altered VLCFA levels
• Cardiovascular disease - Atherosclerosis connections

Therapeutic Targeting

Potential Strategies

• Enzyme inhibitors - Modulate VLCFA synthesis
• Substrate supplementation - Dietary interventions
• Gene therapy - AAV-mediated expression

Research Directions

• Biomarkers - VLCFA levels as disease markers
• Drug development - Selective ELOVL7 modulators
• Combination therapy - Multi-target approaches

Enzyme Mechanism

Catalytic Process

The ELOVL (Elongation of Very Long Chain Fatty Acids) family performs the first and rate-limiting step of fatty acid elongation. ELOVL7 specifically catalyzes the condensation reaction[@tamura2009]:

The reaction proceeds through four enzymatic steps repeated cyclically:

Substrate Specificity

ELOVL7 exhibits distinct substrate preferences[@tamura2009]:

| Substrate Category | Specific Fatty Acids | Product Range |
|-------------------|---------------------|---------------|
| Saturated | C16:0 (palmitoyl), C18:0 (stearoyl) | C22:0, C24:0 |
| Monounsaturated | C16:1, C18:1 (oleoyl) | C22:1, C24:1 |
| Polyunsaturated | C18:2 (linoleoyl), C20:4 (arachidonoyl) | C20-C24PUFAs |

Lipid Raft Biology

Membrane Microdomains

Very long chain fatty acids are enriched in lipid rafts—cholesterol-rich membrane microdomains critical for:

• Signal transduction: Concentrating receptors and signaling molecules
• Membrane trafficking: Facilitating vesicular transport
• Protein sorting: Localizing proteins to specific membrane regions

Implications for Neurodegeneration

Altered VLCFA metabolism affects lipid raft composition in several ways[@acharya2012]:

Brain-Specific Functions

Neuronal Membranes

Neurons have particularly high requirements for VLCFAs:

• Synaptic vesicle membranes: Highly enriched in C22-C24 fatty acids
• Mitochondrial membranes: VLCFA content affects membrane fluidity and function
• Myelin sheaths: Essential for rapid saltatory conduction

Glial Cells

| Cell Type | VLCFA Role |
|-----------|-----------|
| Oligodendrocytes | Myelin sheath formation and maintenance |
| Astrocytes | Lipid transport to neurons |
| Microglia | Inflammatory lipid mediator synthesis |

Therapeutic Targeting Strategies

Enzyme Inhibition

Several approaches for targeting ELOVL7 therapeutically:

| Strategy | Compound Type | Development Status |
|----------|--------------|-------------------|
| Substrate analogs | Competitive inhibitors | Preclinical |
| Antibody-based | Neutralizing antibodies | Research |
| Gene silencing | Antisense oligonucleotides | Discovery |
| Dietary modification | Substrate deprivation | Clinical |

Biomarker Potential

VLCFA levels in biological fluids may serve as biomarkers:

• Plasma VLCFAs: Correlate with disease progression in AD/PD
• Cerebrospinal fluid: May reflect brain lipid metabolism
• Tissue biopsies: Direct measurement of VLCFA content

See Also

• [Fatty Acid Metabolism](/mechanisms/fatty-acid-metabolism)
• [Lipid Rafts](/mechanisms/lipid-rafts)
• [Myelin](/mechanisms/myelin)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Oligodendrocytes](/cell-types/oligodendrocytes)

References